Total pharmaceutical sales in Lithuania during February–April 2009 were EUR 105 (110) million in PPP, which represents a decline of 5% at CER compared to the same period in the previous year. The negative market growth is mainly due to the weak economic situation in Lithuania.
Tamro net sales in Lithuania during February–April were EUR 24 (27) million, a decrease of 10%, mainly due to the general market decline. To compensate for lower sales, Tamro Lithuania successfully introduced extensive cost alignment measures.
Tamro Lithuania’s average market share in wholesale was 14% and in retail 10%. The company employed an average of 605 (383) people, of whom 80% worked in retail.
